Hepatitis D or delta virus (HDV) is an ‘original’ RNA virus that requires the hepatitis B surface antigen (HBsAg) of hepatitis B virus (HBV) for transmission. The worldwide prevalence of HDV infection is difficult to classify. Recently, several systematic reviews have been published on this topic, reporting a worldwide prevalence of between 12 and 70 million. The high range documents the uncertainty and insufficient data quality. One reason for the unclear epidemiological data is that anti-HDV screening is not regularly performed in HBsAg-positive patients. Even in the international guidelines, there are different recommendations on who should be screened for hepatitis D. While the EASL CPG recommends HDV screening in all HBsAg positive patients, the AASLD guidelines recommend it only in patients with a risk profile. Chronic HDV infection is associated with a severe course of hepatitis, often leading to rapid progression of fibrosis, hepatic decompensation, and HCC. Therefore, effective therapeutic options are critical. Until recently, only PEG-IFN was available as a therapeutic option with 25-30% of patients achieving virological response. However, therapy with PEG-IFN cannot be used in many patients with hepatitis D because of contraindications. New therapeutic options are already being tested in phase 3 trials. Very recently, EMA approved the HDV entry inhibitor Bulevirtide at a dose of 2mg s.c. once daily as a therapy for hepatitis D in compensated liver disease. Bulevirtide is a lipopeptide that blocks the function of the HBV receptor NTCP. The basis for this approval is the results of two phase 2 trials that tested bulevirtide in patients with chronic hepatitis D. The primary endpoint of the study, an undetectable HDV RNA concentration or a reduction of ? 2log10 from study entry to week 24, was achieved in approximately 50% of patients and ALT normalized in more than 40%. The therapy was very well tolerated according to the congress reports and also from my own experience. After cessation of therapy, virologic relapse occurs in most patients, so the optimal duration of treatment has not yet been defined. Bulevirtide is also being investigated in combination with PEG-IFN and other drugs with different mechanisms of action (e.g. the prenylation inhibitor lonafarnib) are clinical development. Thus, there are important developments in the treatment of this most severe form of chronic viral hepatitis.